Literature DB >> 21768203

Inflammation-induced up-regulation of TLR2 expression in human endothelial cells is independent of differential methylation in the TLR2 promoter CpG island.

Britta Diesel1, Nadège Ripoche, Rebecca T Risch, Sascha Tierling, Jörn Walter, Alexandra K Kiemer.   

Abstract

Toll-like receptors play an important role in endothelial inflammation; however, little is known on the mechanisms regulating their expression. Differential promoter DNA methylation is an increasingly recognized mechanism that determines a switch between gene silencing and gene transcription. We hypothesized that epigenetic mechanisms are involved in the regulation of endothelial TLR2 expression because of the localization of the TLR2 promoter on a CpG-island. Resting human umbilical vein endothelial cells (HUVECs) displayed rather low TLR2 mRNA expression, while a strong expression increase occurred under inflammatory conditions. We examined the TLR2 promoter methylation pattern in resting HUVECs and compared it to cells treated either with the inflammatory cytokine TNF-α or the DNA-demethylating agent 5-azacytidine. DNA bisulfite conversion was followed by either genomic sequencing or single nucleotide primer extension (SNuPE) HPLC. Results of both techniques showed a low- or non-methylated TLR2 promoter in resting HUVECs and no alteration of the methylation pattern under inflammatory conditions. Whereas 5-azacytidine significantly increased the mRNA expression of the epigenetically regulated gene H19, TLR2 expression was not affected. Taken together, employing different methodological approaches, our data show no implication of methylation pattern changes in inflammatory induction of TLR2 expression in human endothelial cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21768203     DOI: 10.1177/1753425910394888

Source DB:  PubMed          Journal:  Innate Immun        ISSN: 1753-4259            Impact factor:   2.680


  7 in total

1.  Lipid droplets as a novel cargo of tunnelling nanotubes in endothelial cells.

Authors:  Ksenia Astanina; Marcus Koch; Christian Jüngst; Andreas Zumbusch; Alexandra K Kiemer
Journal:  Sci Rep       Date:  2015-06-22       Impact factor: 4.379

2.  Variable promoter methylation contributes to differential expression of key genes in human placenta-derived venous and arterial endothelial cells.

Authors:  Jihoon E Joo; Ursula Hiden; Luciana Lassance; Lavinia Gordon; David J Martino; Gernot Desoye; Richard Saffery
Journal:  BMC Genomics       Date:  2013-07-15       Impact factor: 3.969

Review 3.  The Role of Toll-Like Receptors in Hematopoietic Malignancies.

Authors:  Darlene A Monlish; Sima T Bhatt; Laura G Schuettpelz
Journal:  Front Immunol       Date:  2016-09-28       Impact factor: 7.561

Review 4.  Contribution of Aberrant Toll Like Receptor Signaling to the Pathogenesis of Myelodysplastic Syndromes.

Authors:  Luana Chiquetto Paracatu; Laura G Schuettpelz
Journal:  Front Immunol       Date:  2020-06-17       Impact factor: 7.561

5.  Gene Expression and DNA Methylation Alterations During Non-alcoholic Steatohepatitis-Associated Liver Carcinogenesis.

Authors:  Kostiantyn Dreval; Volodymyr Tryndyak; Aline de Conti; Frederick A Beland; Igor P Pogribny
Journal:  Front Genet       Date:  2019-05-29       Impact factor: 4.599

6.  CpG Single-Site Methylation Regulates TLR2 Expression in Proinflammatory PBMCs From Apical Periodontitis Individuals.

Authors:  María José Bordagaray; Alejandra Fernández; Jessica Astorga; Mauricio Garrido; Patricia Hernández; Alejandra Chaparro; María Jesús Lira; Peter Gebicke-Haerter; Marcela Hernández
Journal:  Front Immunol       Date:  2022-03-01       Impact factor: 7.561

7.  Effects of sevoflurane postconditioning on cell death, inflammation and TLR expression in human endothelial cells exposed to LPS.

Authors:  Raquel Rodríguez-González; Aurora Baluja; Sonia Veiras Del Río; Alfonso Rodríguez; Jaime Rodríguez; Manuel Taboada; David Brea; Julián Álvarez
Journal:  J Transl Med       Date:  2013-04-03       Impact factor: 5.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.